Posted by Michael Wonder on 07 Dec 2020
scPharmaceuticals receives complete response letter from FDA for Furoscix
7 December 2020 - Complete response letter did not identify clinical deficiencies.
scPharmaceuticals today announced it received a complete response letter from the U.S. FDA on 3 December 2020 regarding the Company’s bew drug application for Furoscix.
